Why the next investment frontier in oncology is before treatment

On any given morning in American hospitals, oncology units fill with patients beginning treatment for cancers that have already spread. By the time therapy starts, much of the outcome has already been shaped. Later-stage diagnoses bring more specialists, longer treatment courses, greater risk and rising costs. For many screen-detectable cancers, this moment did not have to arrive so late.

While these moments are clinical, they reflect a deeper structural imbalance in how the United States approaches cancer care. The system has built extraordinary capacity to treat cancer once it progresses, while investing far less in influencing when it is identified. The imbalance is becoming untenable. The US devotes nearly one-fifth of its GDP to healthcare, yet life expectancy and preventable mortality continue to lag peer nations. Within oncology, cancer care is approaching a breaking point. Spending is projected to reach $246 billion by 2030, yet even among highly screenable cancers, millions of patients are still diagnosed only after disease has spread. The disconnect between innovation and impact has left both clinical and financial strain mounting across the system. As this imbalance grows harder to sustain, a pressing question emerges: will the next investment frontier in oncology come before treatment begins?

Any discussion of earlier investment must begin with prevention. Vaccination, tobacco control and other risk-reduction strategies remain foundational to reducing cancer burden, and far more of them could be implemented than is the case today. But prevention does not eliminate risk, nor does it reach all populations equally. Even in a system that fully embraced it, millions of cancers would still occur. When they do, the timing of diagnosis shapes what follows. And that timing is deeply unequal. Nearly half of breast cancer diagnoses in high-poverty areas occur at advanced stages, compared with just over a third in lower-poverty communities, despite available screening. Behind these differences lies something deceptively simple: how quickly people are able to enter the diagnostic system once symptoms appear.

In practice, timing is structured by opportunity, access to care, diagnostic capacity and the ability to navigate the system, factors that also carry tangible financial implications. A SEER-Medicare analysis estimated 10-year treatment costs for breast cancer at roughly $103,573 when detected at stage 0, compared with $376,573 at stage 4. Detecting disease after it has spread more than triples long-term spending. And as these figures capture financial impact, they don’t fully reflect the human burden of more aggressive treatment, prolonged strain and diminished survival.

The persistence of late diagnoses reflects something deeper than the limits of science. It reflects how care is delivered and financed. Advances in prevention, screening and treatment have reduced mortality across many tumour types, but innovation alone does not guarantee broad benefit. Its impact depends on infrastructure: imaging capacity, referral networks, workforce availability and reliable follow-through. Where those systems are fragmented or under-resourced, earlier diagnosis becomes less likely.

Historically, screening services were never built with the same intensity as hospital-based and specialty care. Reimbursement structures rewarded procedures and acute interventions, making returns immediate and visible. Earlier detection, by contrast, produced benefits over longer horizons, often accruing to payers or patients rather than to the organizations making the investment. As a result, investment followed intervention and treatment dominated detection.

That imbalance is no longer sustainable. Economic pressures are forcing a long-delayed recalibration of incentives embedded in how providers are paid. In payment arrangements that hold care organizations accountable for total patient spending, earlier diagnosis carries significant financial weight. The cost of delayed detection is no longer abstract. It appears in hospital utilization, complications and overall expenditures. Under these conditions, late detection becomes an economic liability.

Financial markets are also beginning to price this shift. Capital is increasingly being directed upstream, towards diagnostic services and screening technologies that influence when disease is recognized. One recent illustration is the proposed acquisition of Hologic by Blackstone and TPG. Hologic develops high-resolution mammography systems and AI-enabled diagnostic tools that shape when cancer is identified. Scaling that impact requires more than innovation. It depends on distribution, workforce training, workflow integration and reliable performance across care settings – factors that determine whether earlier detection expands access or remains concentrated in well-resourced systems.

In this deal, early detection is embedded directly into investor return. In FY2025, Hologic generated $844 million in recurring revenue tied to its installed base and ongoing utilization. The proposed $18.3 billion transaction links part of investor return to the performance of its Breast Health segment. Financial returns are therefore tied to sustained adoption of early detection infrastructure.

Some may worry that investing in detection simply moves financial incentives upstream. That concern deserves scrutiny, but so does the reality that current cancer spending trajectories are unsustainable. As financial pressures intensify, earlier detection offers a more stable pathway: fewer complications, more predictable care and greater continuity in delivery. If investment strengthens screening infrastructure in underserved communities, it could also narrow persistent inequities in detection. Alignment alone will not resolve archaic diagnostic disparities, but it creates an opening that did not exist before.

Earlier diagnosis will also not replace prevention, but it can reduce downstream disruption and improve predictability for the entire health system. As payment models evolve, financial return is increasingly linked to utilization and outcomes, directing capital towards earlier diagnosis and system stability. Few areas in medicine align clinical value and economic resilience as clearly as timely detection. Identifying disease before it advances changes the course of treatment before complexity and costs accumulate. It influences when patients enter care and everything that follows.

Oncology units will continue to fill each morning. What can change, and must, is when exactly patients arrive and what options remain available to them when they do. As financial pressure and clinical reality converge, the urgency is to invest as seriously in when disease is found as we have in how it is treated.

The views expressed in this article are those of the authors alone and do not necessarily reflect the views of Nautic Partners, Harvard University or their respective affiliates. The authors have no affiliation with Hologic or with any parties involved in the referenced transaction.